Insider

Davita Inc.

DVA Health Care · 3 analyses · 1 expectation tracked

Davita reported $3.6B in revenue (+4.6% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 1 open management expectation for this company. 1 insider sale recorded.

Mentioned in recent filings: Ukraine Tariffs

What changed

Deals & ownership

Insider Week: What corporate executives bought and sold

Notable transactions by executives and major shareholders from October 24 to October 30: market purchases, sales, and announced plans to sell shares. Disclosure does not indicate how an insider values a company and is not a recommendation to buy or sell.

Company history

October 2026

DAVITA INC.: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-29: Revenue (us-gaap:Revenues), quarter 2026-07-01 to 2026-09-30: 3,578,126,000 USD (3.6 billion; 3,578 million); same period a year earlier (2025-07-01 to 2025-09-30): 3,420,227,000 USD (3.4 billion; 3,420 million); change +4.6% Source
  • 2026-10-29: Revenue (us-gaap:Revenues), year to date 2026-01-01 to 2026-09-30: 10,547,758,000 USD (10.5 billion; 10,548 million); same period a year earlier (2025-01-01 to 2025-09-30): 10,023,282,000 USD (10 billion; 10,023 million); change +5.2% Source
  • 2026-10-29: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 499,255,000 USD (499 million); same period a year earlier (2025-07-01 to 2025-09-30): 505,767,000 USD (506 million); change -1.3% Source
  • 2026-10-29: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 1,560,148,000 USD (1.6 billion; 1,560 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,482,545,000 USD (1.5 billion; 1,483 million); change +5.2% Source
  • 2026-10-29: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 222,931,000 USD (223 million); same period a year earlier (2025-07-01 to 2025-09-30): 150,332,000 USD (150 million); change +48.3% Source
  • 2026-10-29: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 685,858,000 USD (686 million); same period a year earlier (2025-01-01 to 2025-09-30): 512,586,000 USD (513 million); change +33.8% Source
  • 2026-10-29: Diluted EPS (us-gaap:EarningsPerShareDiluted), year to date 2026-01-01 to 2026-09-30: 10.27 USD/shares; same period a year earlier (2025-01-01 to 2025-09-30): 6.62 USD/shares; change +55.1% Source
  • 2026-10-29: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 1,329,730,000 USD (1.3 billion; 1,330 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,345,774,000 USD (1.3 billion; 1,346 million); change -1.2% Source
  • 2026-10-29: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-30: 431,323,000 USD (431 million); same period a year earlier (2025-01-01 to 2025-09-30): 430,434,000 USD (430 million); change +0.2% Source
  • 2026-10-29: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 495,629,000 USD (496 million); previous balance (2025-12-31): 676,438,000 USD (676 million); change -26.7% Source
  • 2026-10-29: Total assets (us-gaap:Assets), as of 2026-09-30: 17,816,512,000 USD (17.8 billion; 17,817 million); previous balance (2025-12-31): 17,480,103,000 USD (17.5 billion; 17,480 million); change +1.9% Source
  • 2026-10-29: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 16,690,695,000 USD (16.7 billion; 16,691 million); previous balance (2025-12-31): 16,321,665,000 USD (16.3 billion; 16,322 million); change +2.3% Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 29, 2026. SEC

LatestEarlierChange
Revenue quarter$3.6B$3.4B+4.6%
Operating income quarter$499M$506M-1.3%
Net income quarter$223M$150M+48.3%
Diluted EPS quarter$3.40$2.04+66.7%
Operating cash flow year to date$1.3B$1.3B-1.2%
Cash and cash equivalents balance$496M$676M-26.7%

Next results expected around January 28, 2027 (estimate: the quarter ending about December 30, 2026 plus the 29 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

3.3Q4 '24*17.2%3.2Q1 '2513.6%3.4Q2 '2515.9%3.4Q3 '2514.8%3.6Q4 '25*15.5%3.4Q1 '2614.1%3.6Q2 '2616.3%3.6Q3 '2614%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Davita Inc. DVA$3.6B+4.6%14.0%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The company expects to offer expanded HD to the vast majority of its eligible patients in November.

    Said October 29, 2026 · Period named: November · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
October 27, 2026Berkshire Hathaway IncSale382,563$180.43$69,026,033SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
Berkshire Hathaway28,697,229$5,019,719,296-0.6%Q3 2026
BlackRock2,733,890$478,212,005+11.1%Q3 2026
State Street1,377,835$241,010,898+4.1%Q3 2026
Geode Capital Management1,255,164$219,266,858+47.0%Q3 2026
Norges Bank (Norway's sovereign fund)344,422$76,627,007—Q2 2026
D. E. Shaw & Co.369,019$64,548,803-42.4%Q3 2026
Citadel Advisors48,207$8,432,369-75.9%Q3 2026
Fidelity (FMR)40,961$7,164,670-64.2%Q3 2026
Bridgewater Associates39,079$6,835,699+255.4%Q3 2026
Two Sigma Investments20,230$4,500,770-58.8%Q2 2026
Wellington Management9,610$2,138,033+305.1%Q2 2026
Renaissance Technologies6,400$1,423,872-96.6%Q2 2026
Millennium Management2,359$412,636-96.9%Q3 2026
T. Rowe Price102,272$17,8900.0%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.